Genetically regulated response to intravesical Bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor

Journal of Urology

Volumn 158, Issue 2, 1997, Pages 646-652

  Kadhim, Salam A ^b   Chin, Joseph L ^a   Batislam, Ertan ^b   Karlik, Stephen J ^b   Garcia, Bertha ^b   Skamene, Emil ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

BCG; Bladder tumor

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CONTROLLED STUDY; FLOW CYTOMETRY; GENE CONTROL; HISTOLOGY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0030739143     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64576-2     Document Type: Article

References (35)

1. Morales, A.: Treatment of carcinoma in situ of the bladder with BCG. A phase II trial. Cancer Immunol. Immunother., 9: 69, 1980.
2. Morales, A.: Long term results of BCG therapy for bladder cancer. J. Urol., 132: 457, 1984.
3. DeJong, W. H., Deboer, E. C., Vandermeijden, A. P. M., Steerenberg, P. A. and Debruyne, F. M. J.: Intravesical BCG administration in guinea pig. II. Immunohistochemical characterization of cellular infiltrate after one or two cycles of intravesical BCG. Virchow's Archiv B, Cell Pathology including Molecular Pathology, 61: 159, 1991.
4. Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. and Catalona, W. J.: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol., 150: 1018, 1993.
5. Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W. J.: Reduction of bladder tumor in mice treated with intravesical Bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res., 43: 1611, 1983.
6. Lamm, D. L.: Carcinoma in situ. Urological Clin. North Am., 19: 499, 1992.
7. Gros, P., Skamene, E. and Forget, A.: Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J. Immunol., 127: 2417, 1981.
8. r) controlling resistance to intracellular parasites. Infect. Immun., 40: 1234, 1983.
9. Skamene, E., Gros, P., Forget, A., Kongshavn, P. A. L., St. Charles, C. and Taylor, B. A.: Genetic regulation of resistance to intracellular pathogens. Nature, 297: 506, 1982.
10. Schurr, E., Malo, D., Radzioch, D., Buschman, E., Morgan, K., Gros, P. and Skamene, E.: Genetic control of innate resistance to mycobacterial infections. Immunol. Today, 12: A42, 1991.
11. Skamene, E. and Pietrangeli, C. E.: Genetics of the immune response to infectious pathogens. Current Opinions in Immunology, 3: 511, 1991.
12. Vidal, S., Tremblay, M., Govoni, G., Gauthier, S., Sebastiani, G., Malo, D., Skamene, E., Olivier, M., Jothy, S. and Gros, P.: The Ity/Lsh/Bcg locus: natural resistance to infection with intra-cellular parasites is abrogated by disruption of the Nramp1 gene. J. Exp. Med., 182: 655, 1995.
13. Vidal, S., Gros, P. and Skamene, E.: Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. J. Leukocyte Biol., 58: 382, 1995.
14. Vidal, S., Malo, D., Vogan, K., Skamene, E. and Gros, P.: Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell, 73: 469, 1993.
15. Schurr, E., Skamene, E., Morgan, M., Chu, L. and Gros, P.: Mapping of Col3a1 and Col6a3 to proximal murine chromosome 1 identifies conserved linkage structural protein genes between murine chromosome 1 and human chromosome 2q. Genomics, 8: 477, 1990.
16. Cellier, M., Govoni, G., Vidal, S., Groulx, N., Liu, J., Sanchez, F., Skamene, E., Schurr, E. and Gros, P.: The human NRAMP gene: cDNA cloning, chromosomal mapping, genomic organization and tissue specific expression. J. Exp. Med., 180: 1741, 1994.
17. Bulbul, M. A., Chin, J. L., Huben, R. P., Englander, L. S. and Pontes, J. E.: The effect of nitrofurantoin on bladder tumor cell lines: in vitro growth and implantation in the cauterized mouse bladder. J. Urol., 134: 1231, 1985.
18. Chin, J. L., Kadhim, S. A., Garcia, B. M., Kim, Y. S. and Karlik, S. J.: Magnetic resonance imaging for detection and treatment monitoring of orthotopic murine detection and treatment monitoring of orthotopic murine bladder tumor implants. J. Urol., 145: 1297, 1991.
19. Weinshenker, B. G., Baas, R. N. and Karlik, S. J.: An open trial of OKT3 in patients with multiple sclerosis. Neurology, 41: 1047, 1991.
20. Fradet, Y., Tardiff, M., Bourget, L., Robert, J. and the Laval University Urology Group: Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res., 50: 432, 1990.
21. Thanhauser, A., Bohle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H. D. and Ulmer, A. J.: The induction of Bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol. Immunother., 40: 103, 1995.
22. + T cells of mycobacteria growing in human macrophages. Science, 260: 984, 1993.
23. + T cells are required for antigen-specific recruitment of neutrophils by BCG-immune spleen cells. Immunology, 75: 414, 1992.
24. Izzo, A. A. and North, R. J.: Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. J. Exp. Med., 176: 581, 1992.
25. Pryor, K., Goddard, J., Goldstein, D., Stricker, P., Russell, P., Golovsky, D. and Penny, R.: Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumor cell killing. Br. J. Cancer, 71: 801, 1995.
26. Marino, P. A. and Adams, D. O.: Interaction of Bacillus Calmette-Guerin activated macrophages and neoplastic cells in vitro. Cellular Immunology, 54: 11, 1980.
27. Adams, D. O. and Hamilton, T. A.: The cell biology of macrophage activation. Ann. Rev. Immunol., 2: 283, 1984.
28. Klostergaard, J., Leroux, M. E. and Hung, M. C.: Cellular models of macrophage tumoricidal effector mechanisms in vitro. J. Immunol., 147: 2802, 1991.
29. Nussler, A. K. and Billiar, T. R.: Inflammation, immunoregulation, and inducible nitric oxide synthase. J. Leuk. Biol., 54: 171, 1993.
30. Sidhu, R. S. and Bollon, A. P.: Tumor necrosis factor activities and cancer therapy - a perspective. Pharmacol. Ther., 57: 79, 1993.
31. Lamm, D. L., Stodgill, V. D. and Stodgill, B. J.: Complications of bacillus calmette guerin immunotherapy in 1278 patients with bladder cancer. J. Urol., 135: 272, 1986.
32. Skamene, E.: The Bcg gene story. Immunobiology, 191: 451, 1994.
33. Farias-Eisner, R., Sherman, M. P., Aeberhard, E. and Chaudhuri, G.: Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc. Natl. Acad. Sci. USA, 91: 9407, 1994.
34. Hakeem, S. and Stevenson, M.: Mechanism of genetically-regulated response to Bacillus-Calmette Guerin immunotherapy for bladder cancer. McGill J. Med., 1: 37, 1995.
35. Hilburger, M. E. and Zwilling, B. S.: Antigen presentation by macrophages from bacille Calmette-Guerin (BCG)-resistant and -susceptible mice. Clin. Exp. Immunol., 96: 225, 1994.